Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04095689
Title TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors The Methodist Hospital System
Indications

triple-receptor negative breast cancer

Therapies

Cyclophosphamide + Docetaxel + Doxorubicin + IL-12 gene + L-NMMA + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.